8-K: Silexion Therapeutics Reports Positive Preclinical Results for SIL204 in Lung Cancer, Advancing Pan-KRAS Treatment Strategy

Silexion Therapeutics announced positive preclinical data for its RNAi therapy SIL204, demonstrating significant efficacy in human lung cancer cell lines and supporting its innovative delivery system, with a Phase 2/3 clinical trial planned for Q2 2026.

Summary

• Silexion Therapeutics announced new positive preclinical data for SIL204, an RNA interference (RNAi) therapy designed for KRAS-driven cancers.
• The study revealed significant dose-dependent inhibition of SIL204 in human lung cancer cells harboring KRAS G12D mutations, highlighting its potential as a versatile therapeutic.
• The results validate Silexion's lipid-conjugated delivery system, which enhances SIL204 drug entrance into tumor cells, overcoming a known barrier for siRNA technology in solid tumors.
• Silexion is currently conducting additional studies into a new, previously untested KRAS mutation, with results expected shortly, which could further establish SIL204 as a potential pan-KRAS treatment.
• The company's dual-route administration strategy, leveraging both intratumoral and systemic delivery, remains on track.
• Silexion continues to prepare for the initiation of a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for the treatment of KRAS-driven solid tumor cancers.
• KRAS mutations are common oncogenic drivers, occurring in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 30% of lung cancers.
• Lung cancer represents a significant opportunity with over 2 million new cases diagnosed globally each year and limited treatment options for patients with KRAS mutations.
• The combined global treatment markets for pancreatic, colorectal, and NSCLC lung cancer are estimated to be worth over US $30 billion annually.
• SIL204 is designed to silence the production of oncogenic KRAS at the genetic level, preventing the production of cancer-driving proteins at their source, unlike small molecule inhibitors that target already-produced proteins.
• This announcement builds on previously reported findings demonstrating SIL204's efficacy in both pancreatic and colorectal cancer models.

Sentiment

Score: 8

Explanation: The announcement details positive preclinical efficacy for a novel RNAi therapy targeting a challenging oncogenic driver (KRAS) in lung cancer, with a clear plan for advancing to Phase 2/3 clinical trials. This represents significant progress for a clinical-stage biotech addressing a large unmet medical need.

Positives

• Significant dose-dependent inhibition of SIL204 observed in human lung cancer cells harboring KRAS G12D mutations.
• Validation of Silexion's lipid-conjugated delivery system, which enhances drug entrance into tumor cells and overcomes a major barrier for siRNA technology in solid tumors.
• New preclinical data provides further validation for SIL204's mechanism of action and broad potential across multiple KRAS-driven cancer types.
• SIL204's design to silence oncogenic KRAS at the genetic level offers a potentially more effective approach than targeting already-produced proteins.
• The company is on track for a Phase 2/3 clinical trial initiation in Q2 2026.
• Ongoing studies into a new, previously untested KRAS mutation could further establish SIL204 as a potential pan-KRAS treatment.
• Previous findings demonstrated SIL204's efficacy in pancreatic and colorectal cancer models, indicating broad therapeutic potential.

Risks

• Silexion's ability to successfully complete preclinical studies and initiate clinical trials.
• The impact of the regulatory environment and compliance complexities.
• Expectations regarding future partnerships or other relationships with third parties.
• Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital.
• Silexion's ability to maintain its Nasdaq listing.
• Other risks and uncertainties set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025.

Future Outlook

Silexion plans to release results shortly from a new study examining SIL204's efficacy on a previously untested KRAS mutation, which, if positive, could establish SIL204 as a potential pan-KRAS treatment. The company remains on track to initiate a Phase 2/3 clinical trial for SIL204 in KRAS-driven solid tumor cancers in Q2 2026.

Management Comments

• "These new findings provide compelling evidence of SIL204's enhanced delivery capabilities in lung cancer models."
• "The ability of our lipid-conjugated siRNA to enter cancer cells represents a significant advantage for clinical applications, potentially overcoming a major challenge in RNAi therapeutics for solid tumors."

Industry Context

The announcement highlights Silexion's RNAi-based strategy as a novel approach to targeting KRAS mutations, which are notoriously difficult to drug with conventional therapies. This positions SIL204 as a potential breakthrough in a significant oncology market, particularly for lung cancer where treatment options for KRAS mutations are limited. The focus on silencing KRAS at the genetic level differentiates it from small molecule inhibitors.

Comparison to Industry Standards

• SIL204's mechanism of action, silencing oncogenic KRAS at the genetic level, is presented as an innovative approach compared to small molecule inhibitors that target already-produced mutant KRAS proteins.
• The lipid-conjugated delivery system is highlighted as overcoming a known barrier for siRNA technology, which is critical for therapeutic efficacy in solid tumors, suggesting an advantage over other siRNA delivery methods.
• The document implicitly compares SIL204's potential as a pan-KRAS treatment to the limited conventional therapeutic approaches available for most KRAS variants.

Stakeholder Impact

• Shareholders: Positive preclinical results and progress towards clinical trials could increase investor confidence and potentially share price.
• Patients: Potential for a new, effective treatment option for difficult-to-treat KRAS-driven cancers, particularly lung cancer.
• Medical Community: New data on RNAi therapy for KRAS mutations could contribute to scientific understanding and treatment paradigms.

Next Steps

• Release results from ongoing studies examining SIL204's efficacy on a new, previously untested KRAS mutation.
• Initiation of a Phase 2/3 clinical trial for SIL204 for the treatment of KRAS-driven solid tumor cancers in Q2 2026.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, SIL204, RNA interference, RNAi, KRAS, lung cancer, non-small cell lung cancer, NSCLC, preclinical study, oncology, biotechnology, cancer therapy, G12D mutation, lipid-conjugated delivery system, solid tumors, clinical trial, pancreatic cancer, colorectal cancer